{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:50Z","timestamp":1787009450355,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Vaccines and Diagnostics Inc"},{"name":"US Office of Public Health Emergency Preparedness"},{"name":"Office of Research and Development Coordination","award":["HHSO100200600012C"],"award-info":[{"award-number":["HHSO100200600012C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/ofid\/ofz107","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T22:11:09Z","timestamp":1551391869000},"source":"Crossref","is-referenced-by-count":14,"title":["Safety and Immunogenicity of MF59-Adjuvanted Cell Culture\u2013Derived A\/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly"],"prefix":"10.1093","volume":"6","author":[{"given":"Sharon E","family":"Frey","sequence":"first","affiliation":[{"name":"School of Medicine, Saint Louis University, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Shakib","sequence":"additional","affiliation":[{"name":"CMAX Clinical Research Pty Ltd., Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornthep","family":"Chanthavanich","sequence":"additional","affiliation":[{"name":"Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[{"name":"Division of Paediatrics, School of Medicine, University of Western Australia, and Vaccine Trials Group, Telethon Kids Institute, Subiaco, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Smith","sequence":"additional","affiliation":[{"name":"Mercy Health Research, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terapong","family":"Tantawichien","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Chulalongkorn University and Queen Saovabha Memorial Institute, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kittel","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Vaccines GmbH, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jaehnig","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Vaccines GmbH, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenaida","family":"Mojares","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Pte Ltd., Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Verma","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Vaccines LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Kanesa-thasan","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Vaccines LLC, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hohenboken","sequence":"additional","affiliation":[{"name":"Seqirus Inc., Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"key\n\t\t\t\t2019040304395724800_CIT0001","unstructured":"World Health Organization. Avian influenza fact sheet. 2014. http:\/\/www.who.int\/mediacentre\/factsheets\/avian_influenza\/en\/. Accessed November 2015."},{"key":"key\n\t\t\t\t2019040304395724800_CIT0002","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3855\/jidc.3329","article-title":"Recognizing true H5N1 infections in humans during confirmed outbreaks","volume":"8","author":"Zaman","year":"2014","journal-title":"J Infect Dev Ctries"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0003","unstructured":"World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003\u20132015. 2015. http:\/\/www.who.int\/influenza\/human_animal_interface\/EN_GIP_20150106 CumulativeNumberH5N1cases.pdf?ua=1. Accessed November 2015."},{"key":"key\n\t\t\t\t2019040304395724800_CIT0004","unstructured":"World Health Organization. Pandemic influenza risk management WHO interim guidance June 2013. 2013. http:\/\/www.who.int\/influenza\/preparedness\/pandemic\/GIP_PandemicInfluenzaRiskManagementInterimGuidance_Jun2013.pdf?ua=1. Accessed November 2015."},{"key":"key\n\t\t\t\t2019040304395724800_CIT0005","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1126\/science.1221466","article-title":"Influenza: options to improve pandemic preparation","volume":"336","author":"Rappuoli","year":"2012","journal-title":"Science"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0006","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2012.05.013","article-title":"A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A\/H1N1 influenza vaccine in adult and elderly populations","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0007","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0008","doi-asserted-by":"crossref","first-page":"e4384","DOI":"10.1371\/journal.pone.0004384","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0009","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0010","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0011","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0012","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1056\/NEJMc0805274","article-title":"Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1","volume":"359","author":"Stephenson","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0013","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1016\/j.vaccine.2013.07.059","article-title":"The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly","volume":"31","author":"Van Buynder","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0014","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","article-title":"Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase \u00bd clinical trial","volume":"28","author":"Keitel","year":"2010","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0015","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0016","unstructured":"Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. 2007. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074786.htm. Accessed November 2015."},{"key":"key\n\t\t\t\t2019040304395724800_CIT0017","unstructured":"European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP\/BWP\/214\/96). 1997. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003945.pdf. Accessed November 2015."},{"key":"key\n\t\t\t\t2019040304395724800_CIT0018","first-page":"136","article-title":"A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A\/H5N1 influenza vaccine in adult and elderly subjects","volume":"53","author":"Czajka","year":"2012","journal-title":"J Prev Med Hyg"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0019","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immunogenicity of an MF59(\u00ae)-adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/infdis\/jiu826","article-title":"Safety and immunogenicity of cell culture-derived A\/H3N2 variant influenza vaccines: a phase I randomized, observer-blind, dose-ranging study","volume":"212","author":"Johnson","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0021","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.vaccine.2012.03.053","article-title":"Assessment of the immunogenicity and safety of varying doses of an MF59\u00ae-adjuvanted cell culture-derived A\/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects","volume":"30","author":"Fukase","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0022","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.vaccine.2012.03.017","article-title":"A randomized clinical trial to identify the optimal antigen and MF59(\u00ae) adjuvant dose of a monovalent A\/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0023","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4161\/21645515.2014.987014","article-title":"Immunogenicity and safety of cell-derived MF59\u00ae-adjuvanted A\/H1N1 influenza vaccine for children","volume":"11","author":"Knuf","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0024","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/INF.0000000000000462","article-title":"Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A\/H1N1 pandemic influenza vaccine in children 6-35 months of age","volume":"33","author":"Knuf","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vaccine.2014.10.085","article-title":"Safety and immunogenicity of an MF59-adjuvanted A\/H1N1 pandemic influenza vaccine in children from three to seventeen years of age","volume":"33","author":"Knuf","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0026","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/INF.0b013e31824b9545","article-title":"Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A\/H1N1 influenza vaccine in children 3 to < 9 years of age","volume":"31","author":"Nassim","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0027","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/hv.29393","article-title":"A dose-ranging study of MF59(\u00ae)-adjuvanted and non-adjuvanted A\/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination","volume":"10","author":"Reisinger","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t2019040304395724800_CIT0028","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s12325-010-0043-4","article-title":"Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A\/H1N1v vaccine in Japanese children","volume":"27","author":"Yasuda","year":"2010","journal-title":"Adv Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/4\/ofz107\/28267069\/ofz107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T04:43:12Z","timestamp":1554266592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz107\/5367274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,3,1]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz107","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,3,1]]}}}